Literature DB >> 22229122

Vaccine design for CD8 T lymphocyte responses.

Richard A Koup1, Daniel C Douek.   

Abstract

Vaccines are arguably the most powerful medical intervention in the fight against infectious diseases. The enormity of the global human immunodeficiency virus type 1 (HIV)/acquired immunodeficiency syndrome (AIDS) pandemic makes the development of an AIDS vaccine a scientific and humanitarian priority. Research on vaccines that induce T-cell immunity has dominated much of the recent development effort, mostly because of disappointing efforts to induce neutralizing antibodies through vaccination. Whereas T cells are known to limit HIV and other virus infections after infection, their role in protection against initial infection is much less clear. In this article, we will review the rationale behind a T-cell-based vaccine approach, provide an overview of the methods and platforms that are being applied, and discuss the impact of recent vaccine trial results on the future direction of T-cell vaccine research.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22229122      PMCID: PMC3234456          DOI: 10.1101/cshperspect.a007252

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Med        ISSN: 2157-1422            Impact factor:   6.915


  117 in total

1.  New class I and II HLA alleles strongly associated with opposite patterns of progression to AIDS.

Authors:  H Hendel; S Caillat-Zucman; H Lebuanec; M Carrington; S O'Brien; J M Andrieu; F Schächter; D Zagury; J Rappaport; C Winkler; G W Nelson; J F Zagury
Journal:  J Immunol       Date:  1999-06-01       Impact factor: 5.422

Review 2.  Targeting human dendritic cell subsets for improved vaccines.

Authors:  Hideki Ueno; Eynav Klechevsky; Nathalie Schmitt; Ling Ni; Anne-Laure Flamar; Sandra Zurawski; Gerard Zurawski; Karolina Palucka; Jacques Banchereau; Sangkon Oh
Journal:  Semin Immunol       Date:  2011-01-28       Impact factor: 11.130

3.  Dendritic cell targeted HIV gag protein vaccine provides help to a DNA vaccine including mobilization of protective CD8+ T cells.

Authors:  Godwin Nchinda; David Amadu; Christine Trumpfheller; Olga Mizenina; Klaus Uberla; Ralph M Steinman
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-16       Impact factor: 11.205

Review 4.  Poxvirus vector-based HIV vaccines.

Authors:  Giuseppe Pantaleo; Mariano Esteban; Bertram Jacobs; Jim Tartaglia
Journal:  Curr Opin HIV AIDS       Date:  2010-09       Impact factor: 4.283

5.  Complication of intramuscular/subcutaneous immune therapy in severely immune-compromised individuals.

Authors:  O Picard; J Lebas; J C Imbert; P Bigel; D Zagury
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1991

6.  A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates.

Authors:  Dan H Barouch; Zhi-yong Yang; Wing-pui Kong; Birgit Korioth-Schmitz; Shawn M Sumida; Diana M Truitt; Michael G Kishko; Janelle C Arthur; Ayako Miura; John R Mascola; Norman L Letvin; Gary J Nabel
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

7.  Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.

Authors:  John W Shiver; Tong-Ming Fu; Ling Chen; Danilo R Casimiro; Mary-Ellen Davies; Robert K Evans; Zhi-Qiang Zhang; Adam J Simon; Wendy L Trigona; Sheri A Dubey; Lingyi Huang; Virginia A Harris; Romnie S Long; Xiaoping Liang; Larry Handt; William A Schleif; Lan Zhu; Daniel C Freed; Natasha V Persaud; Liming Guan; Kara S Punt; Aimin Tang; Minchun Chen; Keith A Wilson; Kelly B Collins; Gwendolyn J Heidecker; V Rose Fernandez; Helen C Perry; Joseph G Joyce; Karen M Grimm; James C Cook; Paul M Keller; Denise S Kresock; Henryk Mach; Robert D Troutman; Lynne A Isopi; Donna M Williams; Zheng Xu; Kathryn E Bohannon; David B Volkin; David C Montefiori; Ayako Miura; Georgia R Krivulka; Michelle A Lifton; Marcelo J Kuroda; Jörn E Schmitz; Norman L Letvin; Michael J Caulfield; Andrew J Bett; Rima Youil; David C Kaslow; Emilio A Emini
Journal:  Nature       Date:  2002-01-17       Impact factor: 49.962

Review 8.  New insights on adenovirus as vaccine vectors.

Authors:  Marcio O Lasaro; Hildegund C J Ertl
Journal:  Mol Ther       Date:  2009-06-09       Impact factor: 11.454

9.  Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.

Authors:  R A Koup; J T Safrit; Y Cao; C A Andrews; G McLeod; W Borkowsky; C Farthing; D D Ho
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

10.  Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses.

Authors:  Richard A Koup; Mario Roederer; Laurie Lamoreaux; Jennifer Fischer; Laura Novik; Martha C Nason; Brenda D Larkin; Mary E Enama; Julie E Ledgerwood; Robert T Bailer; John R Mascola; Gary J Nabel; Barney S Graham
Journal:  PLoS One       Date:  2010-02-02       Impact factor: 3.240

View more
  60 in total

1.  Regulatory T-Cell Activity But Not Conventional HIV-Specific T-Cell Responses Are Associated With Protection From HIV-1 Infection.

Authors:  Laura Pattacini; Jared M Baeten; Katherine K Thomas; Tayler R Fluharty; Pamela M Murnane; Deborah Donnell; Elizabeth Bukusi; Allan Ronald; Nelly Mugo; Jairam R Lingappa; Connie Celum; M Juliana McElrath; Jennifer M Lund
Journal:  J Acquir Immune Defic Syndr       Date:  2016-06-01       Impact factor: 3.731

2.  Manipulating Memory CD8 T Cell Numbers by Timed Enhancement of IL-2 Signals.

Authors:  Marie T Kim; Samarchith P Kurup; Gabriel R Starbeck-Miller; John T Harty
Journal:  J Immunol       Date:  2016-07-20       Impact factor: 5.422

Review 3.  Influenza-induced lung Trm: not all memories last forever.

Authors:  Natalija Van Braeckel-Budimir; John T Harty
Journal:  Immunol Cell Biol       Date:  2017-04-13       Impact factor: 5.126

4.  Antigen-bearing dendritic cells from the sublingual mucosa recirculate to distant systemic lymphoid organs to prime mucosal CD8 T cells.

Authors:  C Hervouet; C Luci; S Bekri; T Juhel; F Bihl; V M Braud; C Czerkinsky; F Anjuère
Journal:  Mucosal Immunol       Date:  2013-06-26       Impact factor: 7.313

5.  Differential impact of magnitude, polyfunctional capacity, and specificity of HIV-specific CD8+ T cell responses on HIV set point.

Authors:  Catherine Riou; Wendy A Burgers; Koleka Mlisana; Richard A Koup; Mario Roederer; Salim S Abdool Karim; Carolyn Williamson; Clive M Gray
Journal:  J Virol       Date:  2013-11-13       Impact factor: 5.103

6.  Mucosal Immunization with a pH-Responsive Nanoparticle Vaccine Induces Protective CD8+ Lung-Resident Memory T Cells.

Authors:  Frances C Knight; Pavlo Gilchuk; Amrendra Kumar; Kyle W Becker; Sema Sevimli; Max E Jacobson; Naveenchandra Suryadevara; Lihong Wang-Bishop; Kelli L Boyd; James E Crowe; Sebastian Joyce; John T Wilson
Journal:  ACS Nano       Date:  2019-10-04       Impact factor: 15.881

7.  Avidity of human T cell receptor engineered CD4(+) T cells drives T-helper differentiation fate.

Authors:  Patrick Adair; Yong Chan Kim; Kathleen P Pratt; David W Scott
Journal:  Cell Immunol       Date:  2015-10-23       Impact factor: 4.868

8.  Shortened Intervals during Heterologous Boosting Preserve Memory CD8 T Cell Function but Compromise Longevity.

Authors:  Emily A Thompson; Lalit K Beura; Christine E Nelson; Kristin G Anderson; Vaiva Vezys
Journal:  J Immunol       Date:  2016-02-22       Impact factor: 5.422

9.  CD8 T-cell priming upon mRNA vaccination is restricted to bone-marrow-derived antigen-presenting cells and may involve antigen transfer from myocytes.

Authors:  Sandra Lazzaro; Cinzia Giovani; Simona Mangiavacchi; Diletta Magini; Domenico Maione; Barbara Baudner; Andrew J Geall; Ennio De Gregorio; Ugo D'Oro; Cecilia Buonsanti
Journal:  Immunology       Date:  2015-08-28       Impact factor: 7.397

Review 10.  Surface engineering for lymphocyte programming.

Authors:  Elana Ben-Akiva; Randall A Meyer; David R Wilson; Jordan J Green
Journal:  Adv Drug Deliv Rev       Date:  2017-05-10       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.